1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      PSMB11 Orchestrates the Development of CD4 and CD8 Thymocytes via Regulation of Gene Expression in Cortical Thymic Epithelial Cells.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          T cell development depends on sequential interactions of thymocytes with cortical thymic epithelial cells (cTECs) and medullary thymic epithelial cells. PSMB11 is a catalytic proteasomal subunit present exclusively in cTECs. Because proteasomes regulate transcriptional activity, we asked whether PSMB11 might affect gene expression in cTECs. We report that PSMB11 regulates the expression of 850 cTEC genes that modulate lymphostromal interactions primarily via the WNT signaling pathway. cTECs from Psmb11-/- mice 1) acquire features of medullary thymic epithelial cells and 2) retain CD8 thymocytes in the thymic cortex, thereby impairing phase 2 of positive selection, 3) perturbing CD8 T cell development, and 4) causing dramatic oxidative stress leading to apoptosis of CD8 thymocytes. Deletion of Psmb11 also causes major oxidative stress in CD4 thymocytes. However, CD4 thymocytes do not undergo apoptosis because, unlike CD8 thymocytes, they upregulate expression of chaperones and inhibitors of apoptosis. We conclude that PSMB11 has pervasive effects on both CD4 and CD8 thymocytes via regulation of gene expression in cTECs.

          Related collections

          Author and article information

          Journal
          J. Immunol.
          Journal of immunology (Baltimore, Md. : 1950)
          The American Association of Immunologists
          1550-6606
          0022-1767
          February 01 2019
          : 202
          : 3
          Affiliations
          [1 ] Institute for Research in Immunology and Cancer, Montreal, Quebec H3C 3J7, Canada.
          [2 ] Department of Medicine, University of Montreal, Montreal, Quebec H3C 3J7, Canada.
          [3 ] Maisonneuve-Rosemont Hospital Research Center, Montreal, Quebec H1T 2M4, Canada.
          [4 ] Department of Molecular and Cell Biology, University of Connecticut, Storrs, CT 06269; and.
          [5 ] Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo 113-0033, Japan.
          [6 ] Institute for Research in Immunology and Cancer, Montreal, Quebec H3C 3J7, Canada; claude.perreault@umontreal.ca.
          Article
          jimmunol.1801288
          10.4049/jimmunol.1801288
          30567730
          91748244-fe80-45af-b251-e2a577c597db
          History

          Comments

          Comment on this article